Pipeline

We are advancing a differentiated and diverse pipeline of small molecule therapeutics that are precisely engineered to be either highly CNS-penetrant or peripherally restricted. Our candidates target three key drivers of disease by resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.